Technical Analysis for JAZZ - Jazz Pharmaceuticals plc

Grade Last Price % Change Price Change
D 120.42 -0.07% -0.09
JAZZ closed down 0.07 percent on Thursday, March 28, 2024, on 64 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Crossed Above 20 DMA Bullish -0.07%
Multiple of Ten Bullish Other -0.07%
Inside Day Range Contraction -0.07%
20 DMA Resistance Bearish 2.11%
Multiple of Ten Bearish Other 2.11%
Down 3 Days in a Row Weakness 2.11%
Down 4 Days in a Row Weakness 2.11%
Down 5 Days in a Row Weakness 2.11%
50 DMA Resistance Bearish -0.31%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 16 hours ago
60 Minute Opening Range Breakout about 17 hours ago
Rose Above Previous Day's High about 21 hours ago
Possible NR7 1 day ago
Possible Inside Day 1 day ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Jazz Pharmaceuticals plc Description

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products for various medical needs in the United States, Europe, and other countries. The company's products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Prialt for the management of severe chronic pain; and FazaClo LD and FazaClo HD, which are orally disintegrating clozapine tablets for the resistant schizophrenia treatment. It also provides Luvox CR to treat obsessive compulsive disorder; Versacloz oral suspension; Caphosol to treat oral mucositis; Quadramet for the treatment of pain in patients whose cancer has spread to the bones; ProstaScint for imaging the extent and spread of prostate cancer; Niravam for the treatment of generalized anxiety and panic disorders; and Parcopa for the symptoms associated with idiopathic Parkinson's disease treatment. In addition, the company offers Collatamp, a surgical implant impregnated with the antibiotic gentamicin; Fomepizole to treat ethylene glycol poisoning; Kidrolase for treating ALL, Leukaemic meningitis, and non-Hodgkin's lymphoma; Xenazine to treat movement disorders associated with Huntington's chorea and hemiballismus; and Custodiol, a ready to use solution used in organ transplantation. Further, it develops Asparec, a pegylated recombinant Erwinia asparaginase that is in Phase I clinical trials for the treatment of patients with ALL with E. coli asparaginase hypersensitivity; and Leukotac, an anti-CD25 monoclonal antibody is in Phase III clinical trials for the treatment of steroid-refractory acute graft vs. host diseases. The company markets its products through its sales representatives, distributors, and wholesalers, as well as through third party vendors. Jazz Pharmaceuticals Public Limited Company is headquartered in Dublin, Ireland.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Cancer Clinical Medicine Pain Drugs Imaging Pharmaceutical Products Monoclonal Antibody Bone Lymphoma Prostate Cancer Antibiotics Chronic Pain Schizophrenia Suspension Transplantation Movement Disorders Narcolepsy Host Disease Pharmacokinetics Acute Lymphoblastic Leukemia Obsessive Compulsive Disorder Oral Hygiene Pegylation Meningitis Organ Transplantation Cataplexy Mucositis Organ Transplant Asparaginase Luvox Cr Oral Mucositis Panic Disorder

Is JAZZ a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 147.98
52 Week Low 111.2506
Average Volume 636,483
200-Day Moving Average 126.84
50-Day Moving Average 122.47
20-Day Moving Average 119.70
10-Day Moving Average 121.97
Average True Range 2.99
RSI (14) 47.37
ADX 15.22
+DI 24.11
-DI 26.15
Chandelier Exit (Long, 3 ATRs) 123.87
Chandelier Exit (Short, 3 ATRs) 124.43
Upper Bollinger Bands 125.32
Lower Bollinger Band 114.08
Percent B (%b) 0.56
BandWidth 9.39
MACD Line -0.53
MACD Signal Line -0.59
MACD Histogram 0.0585
Fundamentals Value
Market Cap 7.58 Billion
Num Shares 63 Million
EPS 0.83
Price-to-Earnings (P/E) Ratio 145.08
Price-to-Sales 2.05
Price-to-Book 2.23
PEG Ratio 92.30
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 122.67
Resistance 3 (R3) 122.79 122.16 122.30
Resistance 2 (R2) 122.16 121.59 122.10 122.17
Resistance 1 (R1) 121.29 121.23 120.98 121.17 122.04
Pivot Point 120.66 120.66 120.50 120.60 120.66
Support 1 (S1) 119.79 120.09 119.48 119.67 118.80
Support 2 (S2) 119.16 119.73 119.10 118.67
Support 3 (S3) 118.29 119.16 118.55
Support 4 (S4) 118.17